Injection Pen Market Size, Share, Growth Report 2032

Injection Pen Market

Injection Pen Market By Therapy (Osteoporosis, Growth Hormone, Diabetes, Cancer, Auto-immune Diseases, Fertility, and Other Therapies), By Product Type (Reusable Injection Pens and Disposable Injection Pens), By End-User (Hospitals & Diagnostic Clinics and Home-care Settings), and By Region – Global and Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, and Forecasts 2022 – 2028

Category: Medical Device Report Format : PDF Pages: 180 Report Code: ZMR-3374 Published Date: Apr-2022 Status : Published

The global injection pen market registered a revenue growth of USD 35.9 billion in 2021 and is projected to reach around USD 58.6 billion by 2028.

Industry Prospective:

The global injection pen market registered a revenue growth of USD 35.9 billion in 2021 and is projected to reach around USD 58.6 billion by 2028. During this period the market is expected to grow with a compound annual growth rate (CAGR) of approximately 7.4 percent. This report study analyzes the injection pen market’s drivers, restraints/challenges, and their impact on the demands during the forecast period. Moreover, key growth opportunities that will strongly support the growth of the market are also covered in this report.

Global Injection Pen Market SizeRequest Free Sample

Injection Pen Market: Overview

An injection pen is used to deliver drugs to the patient's body. Patients can stick to their treatment plans with the aid of injectable pens. This procedure has aided in the improvement of the patient's quality of life as well as the lowering of healthcare costs. The injection pen approach is widely utilized as a self-management therapy option for diabetes and multiple sclerosis, and it is widely used as a drug delivery system by prominent pharmaceutical companies.

COVID-19 Impact:

The COVID-19 pandemic had no substantial influence on the market for injectable pens. During the pandemic, patients who were already utilizing injectable pens for various medicines continued to do so. However, owing to movement limitations, blocked borders, and a drop in overall commerce, the supply chain for injection pens was interrupted. Patients who were infected with COVID-19 and got therapy had a greater chance of developing diabetes. As a result, if the incidence of diabetes rises, so will the demand for injectable pens in the forthcoming years.

Injection Pen Market: Growth Drivers

The increasing prevalence of diabetes is predicted to foster the market growth

In recent years, the incidence of diabetes has risen dramatically. In 2021, according to International Diabetes Federation, around 537 million persons aged 20 to 79 are affected by diabetes. By 2030, the overall number of diabetics is expected to reach 643 million, and by 2045, it will reach 783 million. Diabetes necessitates the administration of injectable drugs on a daily or weekly basis. Due to such a frequent need for drug administration in diabetic patients, injector pens emerged as the best solution. For injectable drug delivery devices, injection pens are becoming the new norm. Because of their simplicity, dependability, and ability to be directly taken by the patients without the assistance of a physician, their popularity has skyrocketed. As a result of the rising incidence of diabetes and other chronic diseases, more attention is being paid to injectable pen technologies in order to efficiently manage the expanding patient pool and improve patient adherence to treatments. All such factors have led to an increase in demand for injection pens, thereby boosting the global injection pen market growth.

Global Injection Pen Market Request Free Sample

Injection Pen Market: Restraints

Growing preference for alternative modes of drug delivery may hinder the growth of the market.

Injection pen devices are not the only option. Needlestick fear and injury are the biggest deterrents to using injection pens. As a result, there are a variety of needle-free devices that have an extra benefit: they do not cause needle phobia, which is a major obstacle to the widespread use of injectable drug therapies. The discomfort associated with daily injections and the necessity of long-term therapy are the main causes of non-complacence in both children and adults. Insulin pen treatment has also been linked to hyperglycemia in certain individuals due to the inability to control the dosage. As a result of their capacity to execute automatic insulin suspension and reduce the danger of hypoglycemia, there has been a change in treatments that deal with diabetes in Europe shifting from insulin pens to insulin pumps. In addition to this, oral insulin administration is favored in developing nations such as Brazil, China, and India because it is simple to use, acceptable, safe, cost-effective, and practical.

Injection Pen Market: Opportunities

High demand for biosimilars to generate ample opportunities for the market during the estimated period.

Biosimilar has seen a considerable surge in demand as a result of their reduced costs when compared to their patented equivalents. Many biologic compounds' patents are about to expire, which will increase demand for biosimilars. Biosimilars and generics are preferred by insurance companies and governments. As many injectables used to treat chronic diseases are biologics, the expiration of patents and rising backing from governments and insurance companies present a chance for the injection pens market to flourish during the projected period. Additionally, the emergence of smart inject pens is also likely to fuel the global injection pen market growth.

Report Scope:

 

Injection Pen Market: Challenges

The lack of trained professionals for innovative delivery methods pose major challenge for market expansion

Inadequate training and learning for the use of innovative delivery methods like injectable pens lead to incorrect use, which puts personnel and patients at risk. In a hospital context, such procedures may have an impact on the use of injectable pens. Furthermore, because the strength of insulin in the injection pen fluctuates, there is a risk of overdosing if the dose strength is not taken into account. Patients neglected to remove the inside cover of a conventional insulin pen needle, resulting in no insulin being given, according to the ISMP's National Medication Errors Reporting Program (MERP). Patients have also been reported to be using normal pen needles without removing the inner needle cover, according to the FDA.

Injection Pen Market: Segmentation

The global injection pen market is classified based on therapy, product type, end-user, and region. Based on the therapy, the global market is split into osteoporosis, growth hormone, diabetes, cancer, auto-immune diseases, fertility, and other therapies. By product type, the market is divided into reusable injection pens and disposable injection pens. The end-user segment is divided into hospitals & diagnostic clinics and home-care settings.

Recent Developments

  • In March 2022, Novo Nordisk launched its first smart insulin pens. The NovoPen Echo Plus and NovoPen 6 are insulin self-injection pens that collect data such as how much and when insulin is injected, then upload the data to an app through near-field communication (NFC) link so that healthcare professionals and patients may examine it.
  • In April 2021, Roche Diabetes Care France and BioCorp unveiled the smart insulin pen device Mallya in France.

Injection Pen Market: Regional Landscape

Asia Pacific to rule the global market during the forecast period

Asia Pacific is estimated to contribute a major share of the global injection pen market during the forecast period. The rising incidence of diabetes, advantageous reimbursement scenarios, and an expanding number of awareness campaigns are all contributing to the Asia Pacific injection pens market's high share. In addition to this, developing healthcare infrastructure and growing acceptance of biosimilars are also adding up to the growth of the market in this region. North America is estimated to account for a significant share of the market owing to the increase in the adoption of injection pens in homecare settings and the growing prevalence of chronic diseases. Europe is also expected to hold a substantial share in the market.

Injection Pen Market: Competitive Landscape

Eli Lilly and Company, Sanofi, Becton, Dickinson and Company, Ypsomed Holding AG, Novo Nordisk A/S, Sun Pharmaceutical Industries Ltd., Pfizer, AstraZeneca plc, F. Hoffmann-La Roche Ltd., and Merck KGaA, among others are some of the dominant players that are operating in the global injection pen market.

Global injection pen market is segmented as follows:

By Therapy

  • Osteoporosis
  • Growth Hormone
  • Diabetes
  • Cancer
  • Auto-immune Diseases
  • Fertility
  • Other Therapies

By Product Type

  • Reusable Injection Pens
  • Disposable Injection Pens

By End User

  • Hospitals & Diagnostic Clinics
  • Home-care Settings

By Region

  • North America
    • The U.S.
    • Canada
  • Europe
    • France 
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table Of Content

Methodology

Free Analysis

FrequentlyAsked Questions

The increasing prevalence of diabetes is predicted to foster market growth. In recent years, the incidence of diabetes has risen dramatically. In 2021, according to International Diabetes Federation, around 537 million persons aged 20 to 79 are affected by diabetes. By 2030, the overall number of diabetics is expected to reach 643 million, and by 2045, it will reach 783 million. Diabetes necessitates the administration of injectable drugs on a daily or weekly basis. Due to such a frequent need for drug administration in diabetic patients, injector pens emerged as the best solution.

According to the Zion Market Research report, the global injection pen market was worth about 35.9 (USD billion) in 2021 and is predicted to grow to around 58.6 (USD billion) by 2028, with a compound annual growth rate (CAGR) of around 7.4 percent.

 

Asia Pacific is estimated to contribute a major share of the global injection pen market during the forecast period. The rising incidence of diabetes, advantageous reimbursement scenarios, and an expanding number of awareness campaigns are all contributing to the Asia Pacific injection pens market's high share. In addition to this, developing healthcare infrastructure and growing acceptance of biosimilars are also adding up to the growth of the market in this region.

 

Eli Lilly and Company, Sanofi, Becton, Dickinson and Company, Ypsomed Holding AG, Novo Nordisk A/S, Sun Pharmaceutical Industries Ltd., Pfizer, AstraZeneca plc, F. Hoffmann-La Roche Ltd., and Merck KGaA, among others are some of the dominant players that are operating in the global injection pen market.

 

 

Choose License Type

  • zion payment modes

HappyClients

Office Address

Contact Us

Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008

Contact #

US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com

We Are On Social

Industry Press Release

We Accept

We have secured system to process your transaction.

  • payment methods

Business Hours

Our support available to help you 24 hours a day, five days a week.

Monday - Friday: 9AM - 6PM

Saturday - Sunday: Closed